A study published in the journal Radiology: Artificial Intelligence found that use of an artificial intelligence (AI) tool improved detection of breast cancers by 5%. Use of the MammoScreen technology also reduced rates of false positives by 6%. The software was developed by French medical imaging software company Therapixel.
The makers claim use of the software does not take longer than doing a regular mammogram.
In October, the company partnered with radiology nonprofit RAD-AID International to make breast cancer screenings more accessible to the poor. The Mammoscreen software was approved for use by the U.S. Food and Drug Administration in March.
Mammograms are the gold standard for finding possible breast cancers, but they can produce false positives. A 2013 study published in Radiology found that only 10% of women who undergo additional diagnostic work after the initial mammogram ultimately end up having cancer. MammoScreen augments 2-dimensional digital mammogram screenings by adding image views and by tagging suspicious areas.
In the present study, 14 radiologists analyzed 240 digital mammography images showing different types of abnormalities, both by regular mammography and by adding Mammoscreen. Using MammoScreen, the radiologists found breast cancer 69% of the time, vs. 66% of the time without the AI software. Use of the tool reduced the rate of false negatives (normal findings even though cancer is present) by about 10%.
Disclaimer: This article does not provide medical advice. Do not take action based solely on this article and always consult with an appropriate healthcare professional. This article is purely for informational purposes.